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Objective/Background: Drug-resistant strains of tuberculosis (TB) represent a major threat to
global TB control. In low- and middle-income countries, resource constraints make it diffi-
cult to identify and monitor cases of resistance using drug susceptibility testing and
culture. Molecular assays such as the GeneXpert Mycobacterium tuberculosis/rifampicin
may prove to be a cost-effective solution to this problem in these settings. The objective
of this study is to evaluate the use of GeneXpert in the diagnosis of pulmonary TB since
it was introduced into two tertiary hospitals in Ghana in 2013.
Methods: A 2-year retrospective audit of clinical cases involving patients who presented
with clinically suspected TB or documented TB not improving on standard therapy and
had samples sent for GeneXpert testing.t Avenue,
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Of the seven cases with final culture and drug susceptibility testing results, six demon-
strated further drug resistance and five of these were multidrug-resistant TB.
Conclusion: These findings call for a scale-up of TB control in Ghana and provide evidence
that the expansion of GeneXpert may be an optimal means to improve case finding and
guide treatment of drug-resistant TB in this setting.
 2016 Production and hosting by Elsevier Ltd. on behalf of Asian African Society for
Mycobacteriology.Introduction
TheWorld Health Organization (WHO) recommends that drug
susceptibility testing (DST) and culture be performed for all
patients with suspected or known tuberculosis (TB) [1]. This
encourages the identification, monitoring, and treatment of
cases of drug resistance and has become standard practice
in many high-income countries [1]. However, in low- and
middle-income countries where TB burden is high and drug
resistance constitutes a real threat to TB control, DSTand cul-
ture are often unavailable or only performed on retreatment
cases [1].
TB guidelines for Ghana currently target medium- and
high-risk individuals for culture and DST. This includes cases
of treatment failure, relapse, or default, contacts of multidrug-
resistant TB (MDR-TB), healthcare workers, and patients with
human immunodeficiency virus (HIV) [2]. However, resource
constraints make it difficult to adhere to these guidelines.
For example, in 2014, the incidence of TB infection in Ghana
was estimated at 44,000, including 11,000 individuals with
HIV coinfection; only 1799 cases were tested for further resis-
tance. As a consequence of the limited availability and use of
culture and DST, the true prevalence of MDR-TB in Ghana is
not known. Moreover, second-line TB drugs are not always
available to thosewho are identified as having drug resistance,
including those with laboratory confirmed MDR-TB [3]. This
allows for the ongoing spread of difficult-to-treat TB strains
and results in avoidable morbidity and mortality.
Molecular assays such as GeneXpert are changing the
landscape of the diagnosis and management of drug-
resistant TB and may prove to be a cost-effective solution to
this problem in a variety of settings [4–6]. GeneXpert uses
real-time polymerase chain reaction to detect the specific
sequence for Mycobacterium tuberculosis as well as that for
rifampicin resistance and can supplement standard diagnos-
tic tools (such as the acid-fast stain, which is the initial test
routinely used in Ghana) [7,8]. Since the endorsement of Gen-
eXpert by WHO in 2010, over 110 low- and middle-income
countries have purchased GeneXpert, many of which have
incorporated it into their diagnostic algorithms for TB [7]. Pre-
liminary data have been promising, showing that more cases
of TB are being identified (including MDR-TB), there is a
shorter time-to-treatment initiation, and TB diagnosis is
becoming decentralized [4,9,10].
This 2-year retrospective audit is the first to evaluate the
use of GeneXpert since it was introduced as a diagnostic tool
into two tertiary hospitals in Ghana in 2013. These findings
call for a scale-up of TB control in Ghana and provideevidence that the expansion of GeneXpert may be an optimal
means to improve case findings and guide management of
drug-resistant strains in this setting.
Materials and methods
A retrospective audit of TB diagnosis by GeneXpert was con-
ducted from February 2013 to January 2015 at two major hos-
pitals in Ghana: Komfo Anokye Teaching Hospital (KATH) and
Korle Bu Teaching Hospital (KBTH). During that time period,
all patients with clinically suspected TB or documented TB
not improving on standard therapy had samples sent for
GeneXpert testing. Demographic data such as referral facility,
age, and sex, as well as HIV status and the results of smear
microscopy were obtained from patient notes or laboratory
request forms. Contingency tables were prepared to deter-
mine the sensitivity of smear microscopy using GeneXpert
as the reference standard.
Samples from a subset of patients had been transported to
Koforidua Regional Hospital for culture on Lowenstein–Jensen
medium followed by DST to rifampicin, isoniazid, ethambu-
tol, and streptomycin. Results were recorded from laboratory
forms. These patients were also individually recalled to deter-
mine their treatment status and outcome.
This study was conducted in collaboration with the
National Tuberculosis Control Program in Ghana. The proto-
col was approved by the Committee on Human Research, as
well as Ethics of the Kwame Nkrumah University of Science
and Technology, Kumasi, Ghana and KATH (CHRPE/
AP/320/15). Written and verbal consent was obtained from
patients who were recalled.
Results
Seven hundred and seventy-nine records were reviewed.
Demographic data were available for all patients. Of the 376
cases of suspected TB who presented or were referred to
KATH, 118 (31.4%) tested positive for TB by GeneXpert. Of
those, 17 (14.4%) were categorized as rifampicin resistant,
100 (84.7%) as rifampicin sensitive, and one (0.8%) as interme-
diate rifampicin sensitive (Fig. 1).
In many cases, smear microscopy and HIV status were
either not documented or the tests were never performed.
Smear microscopy results were available for 190 of 376
patients from KATH. For these participants, the sensitivity
of microscopy using GeneXpert as the standard was 45.3%
(32.8–58.3%; 95% confidence interval). Of the 118 patients pos-
itive for TB by GeneXpert, HIV status was known for 22 of
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Fig. 1 – Flow chart of samples tested for tuberculosis with GeneXpert, including antibiotic sensitivity of those determined to
be rifampicin resistant. Note: DST = drug susceptibility testing; Emb = ethambutol; Inh = isoniazid; KATH = Komfo Anokye
Teaching Hospital; KBTH = Korle Bu Teaching Hospital; NK = not known; Rif = rifampicin; Str = streptomycin;
TB = tuberculosis; + = positive;  = negative.
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coinfected patients, smear was available for six; three (50%)
of those had negative smears.
Of the total 169 TB positive patients, only the 17 patients
with rifampicin resistance had been considered for culture
and DST, and eight of them were ultimately sent for testing.
Culture and DST were not performed on the remaining
patients due to difficulties in transporting the specimens,
poor quality of specimens, or because a specimen was never
collected. One of the eight specimens was contaminated.
Fig. 1 shows the antibiotic sensitivity of the other seven sam-
ples. Six demonstrated further resistance: five (71.4%) new
cases of MDR-TB and one case of polyresistant tuberculosis.
The last sample was rifampicin resistant by GeneXpert but
tested rifampicin sensitive by culture.
Three of the seven patients with culture-confirmed resis-
tance were located during follow-up. One patient was cured
after completion of second-line drugs, one was in the 10th
month of treatment, and the third died while waiting to
obtain treatment. The other four patients did not return to
the clinic for follow-up and could not be located.In KBTH, 51 (11.4%) of 447 had a positive GeneXpert result
for TB, and all of these were rifampicin sensitive. Of 51
TB-positive patients, HIV status was available for 48 and all
were negative. Smear microscopy was not available at KBTH
during the time period audited.Discussion
Currently, WHO estimates that 33% of cases of TB in Ghana
are detected, and that 1.7% of new cases of TB and 17% of
retreatment cases have MDR-TB [3]. This study provides
new evidence that the expansion of GeneXpert would allow
cases of drug-resistant TB to be identified, including MDR-
TB. It also stresses the dire need for improved follow-up with
TB patients and increased availability of second-line drugs to
prevent the widespread transmission of drug-resistant TB
throughout Ghana.
Sensitivity for smear microscopy in this population was
low at 45.3%. A recent Cochrane review found that GeneXpert
is more sensitive and specific than microscopy and increases
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studies, 8880 participants) [11]. The accuracy of initial diag-
nostic testing is especially important in patients with HIV
coinfection, as smears may be negative in up to 61% of these
patients [12]. In this cohort, three (50%) patients with TB and
HIV were smear negative. These findings reiterate the superi-
ority of GeneXpert over smear microscopy as the initial diag-
nostic test for TB in this particular population.
GeneXpert identified 17 total cases of rifampicin resis-
tance. Notably, the drug resistance was only found in patients
presenting to KATH. This could be a result of several factors,
such as higher prevalence of TB in that area or higher rates of
HIV. As HIV testing had not been performed for the majority
of TB positive patients at KATH, it was not possible to deter-
mine the significance of coinfection. In patients with culture
results, a high concordance (86%) was observed between
rifampicin resistance by GeneXpert and DST. This illustrates
the ability of GeneXpert to accurately predict resistance and
serve as a proxy for MDR-TB in this population.
A major advantage of GeneXpert is that it allows for the
rapid initiation of second-line drugs while awaiting DST and
culture [4]. This is the strategy advocated for by the WHO [1];
however, second-line drugs are not always readily available
in Ghana. Ideally, all 17 patients with rifampicin resistance
should have been started on second-line treatmentwhile their
samples were sent for DST and culture. In this cohort, only
eight (47.1%) patients with rifampicin resistance had samples
sent for DST and culture, and even patients with documented
resistance to first-line medications were started or continued
on standard TB therapy. Only two of the patients with resis-
tance were able to access second-line drugs. This may reflect
a national trend; in the past 2 years, laboratory-confirmed
cases of resistance have increased in Ghana, while the num-
ber being started on second-line treatment has decreased
[3,13]. The current practice of managing drug-resistant TB in
Ghana allows for the dissemination of MDR-TB into the com-
munity and represents a major threat to TB control.
Of course, incorporating GeneXpert into the diagnostic
algorithm for TB in Ghanawill present some foreseeable chal-
lenges. Ghana would need to adjust its budget for TB to
accommodate the installation and running costs of GeneX-
pert as well as the costs associated with additional culture,
DST, and second-line drugs. Programs for MDR-TB treatment
would need to be improved, as inadequate support structures
result in poor adherence and treatment default [14]. Ulti-
mately, a scale-up of Ghana’s MDR-TB management will
require a reallocation of TB funding as well as a strategic
management plan. Despite these obstacles, this study’s initial
findings support the feasibility and critical importance of
implementing GeneXpert in Ghana.
Additional research in Ghana is needed to better quantify
the extent and regional distribution of MDR-TB, the relation-
ship with HIV coinfection, and the prevalence of resistance
among new cases compared to retreatment. One of the limi-
tations of this study is that the proportion of resistance in
new cases of TB versus treatment failure could not be calcu-
lated, as those data were not available for individual patients.
In addition, because second-line drugs were not readilyavailable and most patients were lost to follow-up, conclu-
sions could not be drawn about the impact of GeneXpert
on treatment outcomes or mortality. There was also a
significant amount of incomplete documentation in patients’
medical records, either due to human error or the unavailabil-
ity of tests such as smear microscopy or culture and DST. In
spite of these limitations, this study clearly demonstrates
the need for continued operational research around TB in
Ghana as well as the increased availability of GeneXpert,
culture, and sensitivity testing, and second line anti-TB
medications.
Conclusion
Ultimately, universal access to diagnosis and treatment of TB,
including drug-resistant strains, is an achievable and well-
warranted target for Ghana. This requires both the accurate
detection of cases and the availability and induction of appro-
priate drug regimens. This is the first study to demonstrate
the potential of GeneXpert M. tuberculosis/rifampicin to
increase case findings, identify drug resistance, and guide
treatment of TB in Ghana.Conflicts of interest
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